Profile for Alnylam Pharmaceuticals Inc. (ALNY)

$ 145.63   1.51 (+1.05%) Volume: 59.63k 11:02 AM EDT 7-Aug-2020
Business Description:
Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes.
Address: 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142
Telephone: +1 617 551-8200 Website:
Facsimile: +1 617 551-8101 Email: [email protected]
CEO: John M. Maraganore
Employees: 1,323 Market Cap: 16.72b
Issue Type: CS
Auditor: PricewaterhouseCoopers LLP
Last Audit: Unqualified Opinion with Explanation
Indices: N/A
Industry Classifications
Sector: Healthcare CIK: 1178670
Industry: Biotechnology
Sub-Industry:    Biotechnology
NAICS: Pharmaceutical Preparation Manufacturing (325412)
SIC: Pharmaceutical Preparations (2834)